Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Synthekine
Dragonfly Therapeutics
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Boehringer Ingelheim
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
BioNTech SE
Bristol-Myers Squibb
Bristol-Myers Squibb
Seagen Inc.
Genmab
Merck Sharp & Dohme LLC
Seagen Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Astellas Pharma Inc
AstraZeneca
Merck Sharp & Dohme LLC
Xencor, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC
Eli Lilly and Company
Genmab
Hoffmann-La Roche
Merck Sharp & Dohme LLC
iLeukon Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
NeoImmuneTech
Arcus Biosciences, Inc.
Revolution Medicines, Inc.
Verastem, Inc.
Hoffmann-La Roche
Sichuan Baili Pharmaceutical Co., Ltd.
Genmab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
Eli Lilly and Company
Neonc Technologies, Inc.
Bayer
AstraZeneca
Amgen